The role of beta-blockers in the treatment of chronic heart failure.

[1]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[2]  W. Ahmad.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study , 2010 .

[3]  Natasha Wiebe,et al.  Meta-analysis: -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure , 2009, Annals of Internal Medicine.

[4]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[5]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[6]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[7]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[8]  Åke Hjalmarson,et al.  Heart rate: an independent risk factor in cardiovascular disease , 2007 .

[9]  A. Skene,et al.  Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III , 2005, Circulation.

[10]  Ying Hu,et al.  Effect of β-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats , 2005 .

[11]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[12]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[13]  S. Gottlieb,et al.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). , 2005, Journal of the American College of Cardiology.

[14]  D. Pennell,et al.  Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study , 2004, Heart.

[15]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[16]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[17]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[18]  H. Krumholz,et al.  β-Blocker Therapy in Heart Failure: Scientific Review , 2002 .

[19]  A. Gavazzi,et al.  [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[20]  S. Giampaoli,et al.  Heart rate as a predictor of mortality: the MATISS project. , 2001, American journal of public health.

[21]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[22]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[23]  A. Mallet,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001, Circulation.

[24]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[25]  P. Hildebrandt,et al.  Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. , 2000, Journal of the American College of Cardiology.

[26]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[27]  G. Freeman,et al.  beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. , 2000, Circulation.

[28]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[29]  E Kristal-Boneh,et al.  The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study) , 2000, European heart journal.

[30]  K. Woo,et al.  Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. , 1999, Journal of the American College of Cardiology.

[31]  L. Mestroni,et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol , 1999 .

[32]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[33]  J. Kjekshus,et al.  HEART RATE AS A THERAPEUTIC TARGET IN HEART FAILURE , 1999 .

[34]  L Guize,et al.  Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. , 1999, Hypertension.

[35]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[36]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[37]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[38]  S. Jacob,et al.  Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study , 1996, Journal of hypertension.

[39]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[40]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[41]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[42]  R B D'Agostino,et al.  Influence of heart rate on mortality among persons with hypertension: the Framingham Study. , 1993, American heart journal.

[43]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.

[44]  H A Lindberg,et al.  Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. , 1980, American journal of epidemiology.

[45]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[46]  E. Braunwald.  Alterations in the activity of the adrenergic nervous system in heart failure. , 1970, UCLA forum in medical sciences.

[47]  E. Braunwald,et al.  Augmented Sympathetic Neurotransmitter Activity in the Peripheral Vascular Bed of Patients with Congestive Heart Failure and Cardiac Norepinephrine Depletion , 1968, Circulation.

[48]  E. Braunwald,et al.  Fundamental mechanisms in congestive heart failure. , 1968, The American journal of cardiology.

[49]  E. Braunwald,et al.  The Adrenergic Nervous System in the Control of the Normal and Failing Heart , 1965, Proceedings of the Royal Society of Medicine.

[50]  R. Levy,et al.  Transient tachycardia; prognostic significance alone and in association with transient hypertension. , 1945, The Medical press of Egypt.